Arch Therapeutics Inc (ARTH)

[Polyphemus]

Acc to 2017 10K filed w/SEC - Prior joing ABS/Arch in 2006, Norchi was a portfolio manager at Putnam Investments (2002-2004). Prior to that, he was sr. global biotech & international pharma equity analyst at Citigroup Assset Management and a sell-side analyst covering non-US pharma equities at Sanford C Berstein. History of 2006-2004 period is not stated. There is a difference between being a portfolio manager & stock analyhst for a fund and developing a product/technology and a company. Stating that Norchi has the business end covered is not supprted by the published facts. It may be so. However, at this point, one can only hope; time will tell.